Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We have bold plans to train the official mascot (taking in the mail would be a good start), catch up on our reading, and stroll about town in hopes of enjoying the great outdoors. And what about you? This is a good time to start your spring cleaning. You could engage in a little online shopping to spur the economy. Or you could make that vaccine appointment. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …

A rheumatoid arthritis drug from Eli Lilly (LLY) and Incyte (INCY) did not meet the main goal of preventing progression to mechanical ventilation in a late-stage study in hospitalized Covid-19 patients, BioPharmaDive says. Roughly 8% of participants given baricitinib along with standard of care died by day 28 of the trial versus 13.1% on a placebo, a 38% reduction. In a somewhat paradoxical result, however, Lilly said its drug substantially reduced the risk of death by any cause in the trial. Baricitinib was authorized for emergency use in combination with remdesivir for Covid-19 patients needing supplemental oxygen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If fading memory serves, by partnering with Incyte, Lilly may not be in the best of company?

Comments are closed.